

CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 Madrid

Granada, 25 February 2014

RELEVANT FACT OF NEURON BIOPHARMA, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by companies in expansion integrated in the MAB, we hereby puts in knowledge the following information on Neuron Biopharma, S.A. (hereinafter "NEURON" or the "Company").

The Board of Directors of NEURON has agreed at 20 February 2015 in exercise of the delegation conferred upon it by the General Shareholders' Meeting held on 23 June 2013, to launch a capital increase by issuing up 2,312,500 new shares. The shares will belong to the same class and series, will have the same rights and obligations than those shares currently outstanding and will be represented through book entries. The new shares will be issued at their nominal value, 1 EURO and pre-emptive subscription rights of NEURON shareholders will also be recognized. Appropriate proceedings for the capital increase will shortly be started.

We remain at your disposal for any clarification you consider appropriate.

Fernando Valdivieso Amate
Chairman of the Board of Directors